Review



sa treatment  (Dojindo Labs)


Bioz Manufacturer Symbol Dojindo Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Dojindo Labs sa treatment
    Sa Treatment, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 99/100, based on 40737 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sa treatment/product/Dojindo Labs
    Average 99 stars, based on 40737 article reviews
    sa treatment - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    therapeutic medicine 2018  (ATCC)
    97
    ATCC therapeutic medicine 2018
    Therapeutic Medicine 2018, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/therapeutic medicine 2018/product/ATCC
    Average 97 stars, based on 1 article reviews
    therapeutic medicine 2018 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    peroxidase conjugated streptavidin treatment  (Vector Laboratories)
    99
    Vector Laboratories peroxidase conjugated streptavidin treatment
    Peroxidase Conjugated Streptavidin Treatment, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/peroxidase conjugated streptavidin treatment/product/Vector Laboratories
    Average 99 stars, based on 1 article reviews
    peroxidase conjugated streptavidin treatment - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    sa treatment  (Dojindo Labs)
    99
    Dojindo Labs sa treatment
    Sa Treatment, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sa treatment/product/Dojindo Labs
    Average 99 stars, based on 1 article reviews
    sa treatment - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    treatment naïve namd  (SAS institute)
    96
    SAS institute treatment naïve namd
    Visual acuity outcomes from baseline to Months 12 and 24 in patients with <t>nAMD</t> who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.
    Treatment Naïve Namd, supplied by SAS institute, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/treatment naïve namd/product/SAS institute
    Average 96 stars, based on 1 article reviews
    treatment naïve namd - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    curcumin particles after sas treatment  (SAS institute)
    90
    SAS institute curcumin particles after sas treatment
    Visual acuity outcomes from baseline to Months 12 and 24 in patients with <t>nAMD</t> who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.
    Curcumin Particles After Sas Treatment, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/curcumin particles after sas treatment/product/SAS institute
    Average 90 stars, based on 1 article reviews
    curcumin particles after sas treatment - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    treatment emergent parkinsonism (sas)  (SAS institute)
    90
    SAS institute treatment emergent parkinsonism (sas)
    Visual acuity outcomes from baseline to Months 12 and 24 in patients with <t>nAMD</t> who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.
    Treatment Emergent Parkinsonism (Sas), supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/treatment emergent parkinsonism (sas)/product/SAS institute
    Average 90 stars, based on 1 article reviews
    treatment emergent parkinsonism (sas) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    sa (10−4 and 10−3 m) as treatment groups  (Chemie GmbH)
    90
    Chemie GmbH sa (10−4 and 10−3 m) as treatment groups
    Visual acuity outcomes from baseline to Months 12 and 24 in patients with <t>nAMD</t> who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.
    Sa (10−4 And 10−3 M) As Treatment Groups, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sa (10−4 and 10−3 m) as treatment groups/product/Chemie GmbH
    Average 90 stars, based on 1 article reviews
    sa (10−4 and 10−3 m) as treatment groups - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    sa cell treatment hemin  (Frontier Specialty Chemicals Inc)
    95
    Frontier Specialty Chemicals Inc sa cell treatment hemin
    Visual acuity outcomes from baseline to Months 12 and 24 in patients with <t>nAMD</t> who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.
    Sa Cell Treatment Hemin, supplied by Frontier Specialty Chemicals Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sa cell treatment hemin/product/Frontier Specialty Chemicals Inc
    Average 95 stars, based on 1 article reviews
    sa cell treatment hemin - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Visual acuity outcomes from baseline to Months 12 and 24 in patients with nAMD who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.

    Journal: Journal of Clinical Medicine

    Article Title: Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

    doi: 10.3390/jcm14072370

    Figure Lengend Snippet: Visual acuity outcomes from baseline to Months 12 and 24 in patients with nAMD who were treated with IVT-AFL in routine clinical practice (FAS, LOCF). ( a ) Mean BCVA over 24 months. Mean BCVA data are reported based on the nearest VA assessments within monthly ± 15-day-visit windows. ( b ) BCVA (letters) from baseline to Month 12 and Month 24. Error bars denote SD. 1 FAS completers were defined as patients with valid visual acuity assessments at baseline and at Month 12 (360 ± 60 days). BCVA: best-corrected visual acuity; CI: confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study; FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration; SD: standard deviation; VA: visual acuity.

    Article Snippet: Figure S1: Mean change in BCVA from baseline to Month 12 and Month 24 following IVT-AFL treatment in treatment-naïve patients with nAMD compared to baseline BCVA (FAS, LOCF); Figure S2: Mean change in CST measured by OCT (μm) from baseline to Month 12 and Month 24 in patients with treatment-naïve nAMD (FAS, LOCF); Table S1: Ethics approval boards; Table S2: Mean change in CST measured by OCT (μm) from baseline to Month 12 and Month 24 in patients with treatment-naïve nAMD (FAS, LOCF); Table S3: Safety overview culminated over 2 years (SAS).

    Techniques: Standard Deviation

    Letter gains and losses from baseline to Months 12 and 24 in treatment-naïve patients with nAMD following IVT-AFL treatment in routine clinical practice (FAS, LOCF). FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration.

    Journal: Journal of Clinical Medicine

    Article Title: Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

    doi: 10.3390/jcm14072370

    Figure Lengend Snippet: Letter gains and losses from baseline to Months 12 and 24 in treatment-naïve patients with nAMD following IVT-AFL treatment in routine clinical practice (FAS, LOCF). FAS: full analysis set; IVT-AFL: intravitreal aflibercept; LOCF: last observation carried forward; nAMD: neovascular age-related macular degeneration.

    Article Snippet: Figure S1: Mean change in BCVA from baseline to Month 12 and Month 24 following IVT-AFL treatment in treatment-naïve patients with nAMD compared to baseline BCVA (FAS, LOCF); Figure S2: Mean change in CST measured by OCT (μm) from baseline to Month 12 and Month 24 in patients with treatment-naïve nAMD (FAS, LOCF); Table S1: Ethics approval boards; Table S2: Mean change in CST measured by OCT (μm) from baseline to Month 12 and Month 24 in patients with treatment-naïve nAMD (FAS, LOCF); Table S3: Safety overview culminated over 2 years (SAS).

    Techniques: